Episode 168 - January 9, 2026
Episode
60 min
Read time
3 min
AI-Generated Summary
Key Takeaways
- ✓M&A Market Dynamics: Revolution Medicine attracts competing bids from AbbVie and Merck at $28-32 billion valuation, representing premium multiples versus historical oncology deals like Loxo and Array. This follows AstraZeneca's $100 million upfront deal with China's Jacobio for a pan-RAS inhibitor and Lilly's VTYX acquisition. Multiple pan-RAS programs validate the target class, with RevMed's phase 3 pancreatic cancer asset potentially reaching market within two years in high unmet need indication.
- ✓IPO Window Reopens: Actis Pharmaceuticals prices at $18 versus $16-18 range, raises $318 million including $100 million from partner Lilly, and opens at $27 with 10x oversubscription. The radioligand therapy company uses novel mini-protein discovery platform rather than existing peptides, targeting NECTIN-4 initially. Last private raise was $175 million series B in September 2024 from RA Capital, RTW, Janus Henderson, with additional backing from T. Rowe Price, Avidity, Lilly, Bristol Myers, and Merck ventures.
- ✓Follow-On Financing Surge: Companies pull secondary offerings earlier than traditional post-JPMorgan timing, with all deals upsizing and trading double-digit percentages above offer price. Crynetics raises capital following Pulsenify launch exceeding consensus with 200 enrollment forms in first full quarter for niche indication, plus positive congenital adrenal hyperplasia phase 2 data showing glucocorticoid reduction. Strong follow-on performance indicates robust capital availability and investor enthusiasm entering 2026.
- ✓Next-Generation TYK2 Inhibitors: Alumis demonstrates envudacitinib achieves PASI 90 in over 50% of psoriasis patients and PASI 100 in 30-40%, matching J&J's oral IL-23 inhibitor icotrokinra and rivaling biologic efficacy. Takeda's TYK279 shows similar results, reframing oral small molecule potential after Bristol's Sotyktu commercial disappointment. Second-generation TYK2s avoid first-generation liabilities while expanding into psoriatic arthritis, ulcerative colitis, and SLE, with Bristol and Alumis both reporting phase 3 SLE data in 2026.
- ✓Obesity Beyond GLP-1: Arrowhead raises upsized $625 million following ARO-INHBE phase 2 data showing strong efficacy in diabetic obese patients when combined with tirzepatide, despite minimal monotherapy effect in non-diabetic obesity. The siRNA approach targets visceral adipose tissue and liver fat content through novel pathway distinct from GLP-1 mechanisms. Wave Life Sciences pursues similar strategy. Regulatory pathway remains unclear given combination-dependent efficacy, but market validates novel mechanisms addressing muscle preservation and metabolic health beyond weight loss alone.
What It Covers
Biotech Hangout opens 2026 with analysis of strong sector momentum driven by M&A activity, successful IPOs, and positive market sentiment. The XBI trades at 2125, matching November 2021 levels. Discussion covers Revolution Medicine takeover rumors, Actis Pharmaceuticals IPO raising $318 million, emerging obesity mechanisms beyond GLP-1s, and policy concerns including CDC vaccine schedule changes and CMS pricing demonstrations.
Key Questions Answered
- •M&A Market Dynamics: Revolution Medicine attracts competing bids from AbbVie and Merck at $28-32 billion valuation, representing premium multiples versus historical oncology deals like Loxo and Array. This follows AstraZeneca's $100 million upfront deal with China's Jacobio for a pan-RAS inhibitor and Lilly's VTYX acquisition. Multiple pan-RAS programs validate the target class, with RevMed's phase 3 pancreatic cancer asset potentially reaching market within two years in high unmet need indication.
- •IPO Window Reopens: Actis Pharmaceuticals prices at $18 versus $16-18 range, raises $318 million including $100 million from partner Lilly, and opens at $27 with 10x oversubscription. The radioligand therapy company uses novel mini-protein discovery platform rather than existing peptides, targeting NECTIN-4 initially. Last private raise was $175 million series B in September 2024 from RA Capital, RTW, Janus Henderson, with additional backing from T. Rowe Price, Avidity, Lilly, Bristol Myers, and Merck ventures.
- •Follow-On Financing Surge: Companies pull secondary offerings earlier than traditional post-JPMorgan timing, with all deals upsizing and trading double-digit percentages above offer price. Crynetics raises capital following Pulsenify launch exceeding consensus with 200 enrollment forms in first full quarter for niche indication, plus positive congenital adrenal hyperplasia phase 2 data showing glucocorticoid reduction. Strong follow-on performance indicates robust capital availability and investor enthusiasm entering 2026.
- •Next-Generation TYK2 Inhibitors: Alumis demonstrates envudacitinib achieves PASI 90 in over 50% of psoriasis patients and PASI 100 in 30-40%, matching J&J's oral IL-23 inhibitor icotrokinra and rivaling biologic efficacy. Takeda's TYK279 shows similar results, reframing oral small molecule potential after Bristol's Sotyktu commercial disappointment. Second-generation TYK2s avoid first-generation liabilities while expanding into psoriatic arthritis, ulcerative colitis, and SLE, with Bristol and Alumis both reporting phase 3 SLE data in 2026.
- •Obesity Beyond GLP-1: Arrowhead raises upsized $625 million following ARO-INHBE phase 2 data showing strong efficacy in diabetic obese patients when combined with tirzepatide, despite minimal monotherapy effect in non-diabetic obesity. The siRNA approach targets visceral adipose tissue and liver fat content through novel pathway distinct from GLP-1 mechanisms. Wave Life Sciences pursues similar strategy. Regulatory pathway remains unclear given combination-dependent efficacy, but market validates novel mechanisms addressing muscle preservation and metabolic health beyond weight loss alone.
- •Policy Overhang Persists: CDC removes six vaccines from recommended pediatric schedule without ACIP discussion, including rotavirus, COVID, influenza, meningococcal, hepatitis A, and reduces HPV to single dose. Insurance coverage remains unchanged, limiting immediate commercial impact. CMS most-favored-nation demonstration announcement generates minimal market reaction, suggesting investors either dismiss implementation probability or underestimate impact. Market resilience to policy headlines creates downside risk if significant pricing reform materializes, as investor desensitization may delay appropriate risk assessment.
Notable Moment
Zenas BioPharma's obexelimab data for IgG4-related disease showed only 56% flare reduction versus Uplizna's 87% in cross-trial comparison, despite positive headline framing. The CD19/FcRIIb dual-targeting mechanism failed to demonstrate superiority over CD19-only approach, disappointing investors expecting enhanced potency from co-engagement strategy. The company proceeds with FDA and EMA filings, positioning weekly subcutaneous dosing as differentiation versus Uplizna's intravenous administration.
You just read a 3-minute summary of a 57-minute episode.
Get Biotech Hangout summarized like this every Monday — plus up to 2 more podcasts, free.
Pick Your Podcasts — FreeKeep Reading
More from Biotech Hangout
Episode 180 - April 17, 2026
Apr 17 · 53 min
The Mel Robbins Podcast
Do THIS Every Day to Rewire Your Brain From Stress and Anxiety
Apr 27
More from Biotech Hangout
Episode 179 - April 10, 2026
Apr 10 · 59 min
The Model Health Show
The Menopause Gut: Why Metabolism Changes & How to Reclaim Your Body - With Cynthia Thurlow
Apr 27
More from Biotech Hangout
We summarize every new episode. Want them in your inbox?
Similar Episodes
Related episodes from other podcasts
The Mel Robbins Podcast
Apr 27
Do THIS Every Day to Rewire Your Brain From Stress and Anxiety
The Model Health Show
Apr 27
The Menopause Gut: Why Metabolism Changes & How to Reclaim Your Body - With Cynthia Thurlow
The Rest is History
Apr 26
664. Britain in the 70s: Scandal in Downing Street (Part 3)
The Learning Leader Show
Apr 26
685: David Epstein - The Freedom Trap, Narrative Values, General Magic, The Nobel Prize Winner Who Simplified Everything, Wearing the Same Thing Everyday, and Why Constraints Are the Secret to Your Best Work
The AI Breakdown
Apr 26
Where the Economy Thrives After AI
This podcast is featured in Best Health Podcasts (2026) — ranked and reviewed with AI summaries.
You're clearly into Biotech Hangout.
Every Monday, we deliver AI summaries of the latest episodes from Biotech Hangout and 192+ other podcasts. Free for up to 3 shows.
Start My Monday DigestNo credit card · Unsubscribe anytime